Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Chang Chen et al.
 
ChiCTR2000030254
RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
120/120 inconclusive
  • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

Solaymani-Dodaran
 
IRCT20200318046812N1
RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
193/187 inconclusive
    4 studies excluded by filtering options (1 RCT / 3 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).